Efficacy and Safety Study of Adjunctive Troriluzole in ... | 合法藥品大搜索

Troriluzole is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Read More

2021年1月4日 — Troriluzole is a new chemical entity and third-generation glutamate modulating agent that normalizes glutamate, a key neurotransmitter ... Read More

2021年1月22日 — Troriluzole is a prodrug formulation of riluzole, a medication used to treat amyotrophic lateral sclerosis. Following oral administration ... Read More

2021年5月6日 — Investigators concluded that troriluzole used as an adjunctive treatment for adults with OCD revealed consistent improvement in obsessive- ... Read More

Troriluzole (BHV 4157) is a third generation, tripeptide, glutamate modulator, being developed by Biohaven Pharmaceuticals, for the treatment of ... Read More

2021年4月23日 — Post hoc analysis of data from a phase 2/3 clinical trial (NCT02960893) of troriluzole (Biohaven; New Haven, CT) for spinocerebellar ataxia ... Read More

2021年1月28日 — Troriluzole is an oral, once daily, tablet that is a third-generation prodrug and new chemical entity that modulates glutamate, the most abundant ... Read More

Troriluzole | C15H16F3N5O4S | CID 121488186 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological ... Read More

2020年11月23日 — Obsessive-Compulsive Disorder, Drug: Troriluzole Drug: Placebo, Phase 3 ... Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder. Read More